Subscribe To

Price Alert Latest News Economic Calendar News

VPHIF / Valeo Pharma announces another major milestone for its two innovative asthma therapies

Valeo Pharma Inc. (CSE:VPH, OTCQB:VPHIF) has told investors that its two innovative asthma therapies, Atectura Breezhaler and Enerzair Breezehaler have been accepted for reimbursement by the Ontario Drug Benefit program, the Manitoba Pharmacare Program, the New Brunswick Drug plan, and the Non-Insured Health Benefits (NIHB) and Veterans Affairs Canada (VAC) federal programs. The Kirkland, Quebec-headquartered company noted that the public reimbursments are now in effect except for the Ontario listing which takes effect on February 28, 2022. Read More

Demo Live Account See Partner Details

Content Topics

Valeo

Pharma

Announces

Another

Major

Milestone

Innovative

Asthma

Therapies

Stock

VPHIF

Posted: Feb 24 2022, 09:28

Author Name: Proactive Investors

VPHIF News

By Proactive Investors
October 5, 2023

Valeo Pharma CEO credits Enerzair for strong position on Canada's top-growing companies list

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) CEO Steve Saviuk joined Proactive's Stephen Gunnion to discuss the company's strong position on the Globe an

By Proactive Investors
October 4, 2023

Valeo Pharma secures spot on Canada's top-growing companies list

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) highlighted to investors that it has placed at spot 151 on the Globe and Mail's Report on Business annual lis

By Proactive Investors
September 14, 2023

Valeo Pharma reports record quarterly revenue or strong demand for Enerzair and Atectura therapies

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has reported its seventh consecutive rise in revenues to a quarterly record due to strong growth in its Enerz

By Proactive Investors
September 1, 2023

Valeo Pharma raises funds totalling $4.5M

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has closed a non-brokered private placement offering, raising gross proceeds of $3.92 million. The company a

By Proactive Investors
June 22, 2023

Valeo Pharma bolsters board with two new directors

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said Tamara Close and Didier Leconte have both joined its board of directors, noting that following the appo

By Proactive Investors
June 14, 2023

Valeo Pharma reports record quarterly revenues

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has reported record quarterly revenues of $13.6 million for its second quarter ending April 30, 2023, repr

By Proactive Investors
May 25, 2023

Valeo Pharma expects 2Q revenues to set quarterly record

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said it expects revenues in the second quarter to exceed $13.5 million, a quarterly record, with operating ex

By Proactive Investors
March 16, 2023

Valeo Pharma reports record 1Q revenue and gross profit buoyed by new products and higher market share

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said its revenue for the first quarter ended January 31, 2023, rose by 210% to a record $13.2 million, up fro

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.